Send to

Choose Destination
Oncoimmunology. 2013 May 1;2(5):e24320.

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma.

Author information

Division of Surgical Oncology; Massachusetts General Hospital; Boston MA USA.


The combination of BRAF-targeted agents with immune checkpoint inhibitors represents a recent advance in the treatment of melanoma, even though each of these therapeutic approaches alone has specific limitations. Increasing evidence suggests indeed the existence of a synergistic interaction between these therapeutic modalities.


BRAF; PDL1; checkpoint blockade; immunotherapy; melanoma

Supplemental Content

Full text links

Icon for Taylor & Francis Icon for PubMed Central
Loading ...
Support Center